WO2005030766A8 - Phenyl - carboxamide compounds useful for treating pain - Google Patents

Phenyl - carboxamide compounds useful for treating pain

Info

Publication number
WO2005030766A8
WO2005030766A8 PCT/US2004/030824 US2004030824W WO2005030766A8 WO 2005030766 A8 WO2005030766 A8 WO 2005030766A8 US 2004030824 W US2004030824 W US 2004030824W WO 2005030766 A8 WO2005030766 A8 WO 2005030766A8
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
compounds useful
treating pain
carboxamide compounds
phenylene compound
Prior art date
Application number
PCT/US2004/030824
Other languages
French (fr)
Other versions
WO2005030766A1 (en
Inventor
Qun Sun
Original Assignee
Euro Celtique Sa
Qun Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2004276251A priority Critical patent/AU2004276251B2/en
Priority to DE602004014791T priority patent/DE602004014791D1/en
Priority to CA002537010A priority patent/CA2537010A1/en
Priority to EP04784626A priority patent/EP1664041B1/en
Application filed by Euro Celtique Sa, Qun Sun filed Critical Euro Celtique Sa
Priority to SI200430858T priority patent/SI1664041T1/en
Priority to PL04784626T priority patent/PL1664041T3/en
Priority to DK04784626T priority patent/DK1664041T3/en
Priority to JP2006527125A priority patent/JP4634385B2/en
Publication of WO2005030766A1 publication Critical patent/WO2005030766A1/en
Publication of WO2005030766A8 publication Critical patent/WO2005030766A8/en
Priority to US11/386,058 priority patent/US7799807B2/en
Priority to HK06113225A priority patent/HK1094191A1/en
Priority to HR20080492T priority patent/HRP20080492T3/en
Priority to US12/846,689 priority patent/US7964606B2/en
Priority to US13/158,267 priority patent/US8129388B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides

Abstract

The present invention discloses compounds of formula: (I) (II) where Ar1, Ar2, X, R1, R2, R3, m, and n are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Phenylene Compound”); compositions comprising an effective amount of a Phenylene Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Phenylene Compound.
PCT/US2004/030824 2003-09-22 2004-09-21 Phenyl - carboxamide compounds useful for treating pain WO2005030766A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PL04784626T PL1664041T3 (en) 2003-09-22 2004-09-21 Phenyl-carboxamide compounds useful for treating pain
CA002537010A CA2537010A1 (en) 2003-09-22 2004-09-21 Phenyl - carboxamide compounds useful for treating pain
EP04784626A EP1664041B1 (en) 2003-09-22 2004-09-21 Phenyl-carboxamide compounds useful for treating pain
JP2006527125A JP4634385B2 (en) 2003-09-22 2004-09-21 Phenyl-carboxamide compounds useful for the treatment of pain
SI200430858T SI1664041T1 (en) 2003-09-22 2004-09-21 Phenyl-carboxamide compounds useful for treating pain
DE602004014791T DE602004014791D1 (en) 2003-09-22 2004-09-21 PHENYLIC ACIDIC ACID AMID COMPOUNDS SUITABLE FOR THE TREATMENT OF PAIN
DK04784626T DK1664041T3 (en) 2003-09-22 2004-09-21 Phenylcarboxamide compounds suitable for the treatment of pain
AU2004276251A AU2004276251B2 (en) 2003-09-22 2004-09-21 Phenyl - carboxamide compounds useful for treating pain
US11/386,058 US7799807B2 (en) 2003-09-22 2006-03-20 Therapeutic agents useful for treating pain
HK06113225A HK1094191A1 (en) 2003-09-22 2006-11-30 Phenyl-carboxamide compounds useful for treating pain
HR20080492T HRP20080492T3 (en) 2003-09-22 2008-10-01 Phenyl-carboxamide compounds useful for treating pain
US12/846,689 US7964606B2 (en) 2003-09-22 2010-07-29 Therapeutic agents useful for treating pain
US13/158,267 US8129388B2 (en) 2003-09-22 2011-06-10 Therapeutic agents useful for treating pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50467903P 2003-09-22 2003-09-22
US60/504,679 2003-09-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/386,058 Continuation US7799807B2 (en) 2003-09-22 2006-03-20 Therapeutic agents useful for treating pain

Publications (2)

Publication Number Publication Date
WO2005030766A1 WO2005030766A1 (en) 2005-04-07
WO2005030766A8 true WO2005030766A8 (en) 2006-03-02

Family

ID=34392933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030824 WO2005030766A1 (en) 2003-09-22 2004-09-21 Phenyl - carboxamide compounds useful for treating pain

Country Status (17)

Country Link
US (3) US7799807B2 (en)
EP (2) EP1664041B1 (en)
JP (2) JP4634385B2 (en)
CN (1) CN1856489A (en)
AT (2) ATE399782T1 (en)
AU (1) AU2004276251B2 (en)
CA (1) CA2537010A1 (en)
CY (2) CY1108367T1 (en)
DE (2) DE602004014791D1 (en)
DK (2) DK1664041T3 (en)
ES (2) ES2309564T3 (en)
HK (1) HK1094191A1 (en)
HR (2) HRP20080492T3 (en)
PL (2) PL2017276T3 (en)
PT (2) PT2017276E (en)
SI (2) SI2017276T1 (en)
WO (1) WO2005030766A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867516B2 (en) 2001-01-29 2011-01-11 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
DK1867644T3 (en) * 2003-07-24 2009-09-21 Euro Celtique Sa Heteroberl-tetrahydropyridyl compounds useful for treating or preventing pain
WO2005030766A1 (en) * 2003-09-22 2005-04-07 Euro-Celtique S.A. Phenyl - carboxamide compounds useful for treating pain
PL1664016T3 (en) * 2003-09-22 2009-04-30 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1685109A2 (en) 2003-10-07 2006-08-02 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
CA2616079C (en) 2005-07-22 2012-09-25 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
PE20081692A1 (en) 2007-01-24 2008-12-18 Mochida Pharm Co Ltd NEW DERIVATIVE OF HETEROCICLIDEN ACETAMIDA
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
JP2011057661A (en) * 2009-08-14 2011-03-24 Bayer Cropscience Ag Pesticidal carboxamides
US8921373B2 (en) 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
GB201100420D0 (en) * 2011-01-11 2011-02-23 Rovipak Packaging Solutions Ltd Packaging system
JP6130827B2 (en) 2011-05-17 2017-05-17 塩野義製薬株式会社 Heterocyclic compounds
SG195136A1 (en) 2011-06-22 2013-12-30 Purdue Pharma Lp Trpv1 antagonists including dihydroxy substituent and uses thereof
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
MX364934B (en) * 2012-05-31 2019-03-28 Univ Kinki Agent for preventing and/or treating peripheral neuropathic pain caused by anti-cancer drug.
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
DE102022104759A1 (en) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-crystal screening method, in particular for the production of co-crystals

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5198459A (en) 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
DE3822792C2 (en) 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
KR950703280A (en) 1992-09-09 1995-09-20 미리암 디.메코너헤이 Herbicidal Benzene Compounds
DE4234295A1 (en) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carboxylic acid derivatives, medicaments containing these compounds and process for their preparation
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
GB2276163A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Pyridine compounds.
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5762925A (en) 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
CA2224517A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5840720A (en) 1995-10-23 1998-11-24 Tong-Ho Lin 4-O and 5-aminomethylation of synthetic capsaicin derivatives, a new discovery of capsaicin antagonist
WO1998020867A1 (en) 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
CA2298540A1 (en) 1997-08-20 1999-02-25 David J. Julius Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
EP0943683A1 (en) 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
WO2000039117A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
NZ516743A (en) * 1999-08-04 2004-02-27 Icagen Inc Methods for treating or preventing pain and anxiety
DE10010422A1 (en) * 2000-03-03 2001-09-06 Bayer Ag New 6-(4-carboxy-phenyl)-dihydropyridazinone esters or amides, having erythropoietin sensitizing and erythropoiesis stimulating activity, useful for treating anemia
WO2002016319A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea compounds and the pharmaceutical compositions containing the same
WO2003068749A1 (en) 2002-02-15 2003-08-21 Glaxo Group Limited Vanilloid receptor modulators
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
ATE444289T1 (en) 2002-07-30 2009-10-15 Banyu Pharma Co Ltd ANTAGONIST OF THE MELANIN CONCENTRATING HORMONES RECEPTOR, CONTAINING A BENZIMIDAZOLE DERIVATIVE AS THE ACTIVE INGREDIENT
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
US20060100245A1 (en) * 2002-12-19 2006-05-11 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues
BR0317430A (en) 2002-12-20 2005-10-25 Pharmacia Corp Mitogen-activated protein kinase-activated protein kinase-2 inhibitor compounds
ATE450533T1 (en) 2003-02-14 2009-12-15 Glaxo Group Ltd CARBOXAMIDE DERIVATIVES
US7067509B2 (en) 2003-03-07 2006-06-27 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
AU2004242865A1 (en) 2003-06-02 2004-12-09 F. Hoffmann-La Roche Ag Benzamide nitrile derivatives
JP2007516196A (en) 2003-07-02 2007-06-21 ガラパゴス エヌブイ Pyrazine and pyralidine derivatives as Rho kinase inhibitors
WO2005016323A2 (en) 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
PL1664016T3 (en) 2003-09-22 2009-04-30 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2005030766A1 (en) 2003-09-22 2005-04-07 Euro-Celtique S.A. Phenyl - carboxamide compounds useful for treating pain
US20050130954A1 (en) 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
EP2266569A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors

Also Published As

Publication number Publication date
DK2017276T3 (en) 2011-04-18
ES2309564T3 (en) 2008-12-16
EP1664041B1 (en) 2008-07-02
PT2017276E (en) 2011-04-05
SI1664041T1 (en) 2008-12-31
HRP20080492T3 (en) 2008-11-30
HK1094191A1 (en) 2007-03-23
US20110281876A1 (en) 2011-11-17
CA2537010A1 (en) 2005-04-07
CN1856489A (en) 2006-11-01
ATE496048T1 (en) 2011-02-15
PL2017276T3 (en) 2011-06-30
EP1664041A1 (en) 2006-06-07
PL1664041T3 (en) 2008-12-31
CY1111951T1 (en) 2015-11-04
HRP20110252T1 (en) 2011-05-31
US7964606B2 (en) 2011-06-21
ATE399782T1 (en) 2008-07-15
DK1664041T3 (en) 2008-10-27
US20110009418A1 (en) 2011-01-13
JP5264841B2 (en) 2013-08-14
EP2017276A1 (en) 2009-01-21
DE602004014791D1 (en) 2008-08-14
WO2005030766A1 (en) 2005-04-07
AU2004276251A1 (en) 2005-04-07
JP2007505929A (en) 2007-03-15
DE602004031163D1 (en) 2011-03-03
JP4634385B2 (en) 2011-02-16
ES2360152T3 (en) 2011-06-01
JP2011006463A (en) 2011-01-13
PT1664041E (en) 2008-09-15
AU2004276251B2 (en) 2008-02-07
US20060235022A1 (en) 2006-10-19
SI2017276T1 (en) 2011-05-31
CY1108367T1 (en) 2014-02-12
US8129388B2 (en) 2012-03-06
US7799807B2 (en) 2010-09-21
EP2017276B1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
HK1091481A1 (en) Therapeutic agents useful for treating pain
WO2005056524A3 (en) Therapeutic agents useful for treating pain
MXPA05013587A (en) Therapeutic agents useful for treating pain.
EA200500814A1 (en) DERIVATIVES OF PYRROPOLYMIDININE
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
WO2004029031A3 (en) Therapeutic piperazine compounds
WO2007112000A3 (en) Treatment of pain
TW200639159A (en) Treatment of pain
DE60324544D1 (en) MUSCARIN ANTAGONISTS
BRPI0415179A (en) amide derivatives such as ion channel ligands and pharmaceutical compositions and methods of employing them
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
DK1458393T3 (en) Substituted diketopiperazines as oxytocin antagonists
EA200301203A1 (en) NEW COMPOUNDS AND COMPOSITIONS AS KATEPSIN INHIBITORS
EA200601249A1 (en) PIPERASINS, SUITABLE FOR THE TREATMENT OF PAIN
WO2004033423A3 (en) Anticancer compounds
BR0311970A (en) New compounds, their use and preparation
WO2007058639A3 (en) Antibacterial agents
NO20032411D0 (en) Use of substituted 6-dimethylaminomethyl-1-phenylcyclohexane compounds for the treatment of urinary incontinence
WO2005035500A3 (en) Therapeutic agents useful for treating pain
ATE346080T1 (en) STEROID COMPOUNDS WITH ANTI-TUMORAL EFFECT
TW200510348A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480027348.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2537010

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004276251

Country of ref document: AU

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN OFFICIAL GAZETTE 14/2005 UNDER (71) THE ADDRESS SHOULD READ "122, BOULEVARD DE LA PETRUSSE, L-2330 (LU)"

WWE Wipo information: entry into national phase

Ref document number: 2004784626

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11386058

Country of ref document: US

Ref document number: 2006527125

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/003214

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2004276251

Country of ref document: AU

Date of ref document: 20040921

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004276251

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004784626

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11386058

Country of ref document: US